Rallybio Corp Income Statement
RLYB|2 years of annual SEC 10-K data (FY2024-FY2025)
Line items include revenue, cost of goods sold, gross profit, operating expenses, interest, taxes, and net income with per-share data across 2 fiscal years. All figures from audited SEC 10-K filings.
At a glance
Revenue
$636,000
FY2025
Gross Profit
N/A
FY2025
Operating Income
-$60M
FY2025
Net Income
-$58M
FY2025
Rallybio Corp reported $636,000 in revenue and $58M in net loss for FY2025. Revenue increased 6.0% from FY2024 to FY2025.
Based on SEC 10-K filings.
Key Data Points
- Altman Z-Score NaN (distress zone, below 1.23 threshold)
- Currently unprofitable: Net income is negative
- Cash-backed earnings: Operating cash flow exceeds net income
Data sourced from SEC EDGAR filings. Not investment advice.
| Item | FY2025 | FY2024 |
|---|---|---|
| Revenue | $636.0K | $600.0K |
| SG&A Expense | $19.6M | $25.4M |
| R&D Expense | $41.5M | $53.5M |
| Operating Income | -$60.5M | -$78.9M |
| Income Tax | $0 | $0 |
| Net Income | -$57.8M | -$74.6M |
| EPS (Basic) | -$10.61 | -$1.84 |
| EPS (Diluted) | -$10.61 | -$1.84 |
| Shares Outstanding | 5.2M | 37.8M |
| Operating Margin | -9512.0% | -13155.3% |
| Profit Margin | -9084.1% | -12427.3% |